Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study

• Principais autores: Li Wang (Autor), Xiaolin Li (Autor), Bin Zhao (Autor), Dan Mei (Autor), Jiandong Jiang (Autor), Jingli Duan (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2021-09-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Introduction: Immune checkpoint inhibitors (ICIs) have substantially improved the clinical outcomes of various malignancies. However, the adverse event of tumor lysis syndrome (TLS) has not been included in the National Comprehensive Cancer Network guidelines or drug inserts. In this study, we aimed...